{
    "Clinical Trial ID": "NCT00331630",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment With Lapatinib and Abraxane",
        "  30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.",
        "  lapatinib ditosylate: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.",
        "  paclitaxel albumin-stabilized nanoparticle formulation: 30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed breast cancer",
        "  Clinical stage I-III disease",
        "  Measurable disease defined as  1 unidimensionally measurable lesion  20 mm by conventional techniques OR  10 mm with spiral CT scan",
        "  HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization",
        "  No known brain metastases",
        "  Hormone receptor status unspecified",
        "  PATIENT CHARACTERISTICS:",
        "  Menopausal status not specified",
        "  Male or female",
        "  Life expectancy > 12 weeks",
        "  ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%",
        "  WBC  3,000/mm^3",
        "  Absolute neutrophil count  1,500 mm^3",
        "  Platelet count  100,000/mm^3",
        "  Total bilirubin normal",
        "  AST and ALT  2.5 times upper limit of normal",
        "  Creatinine normal OR creatinine clearance  60 mL/min",
        "  LVEF  50% as measured by echocardiogram or MUGA scan",
        "  No other malignancy within the past year",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  Able to swallow and retain oral medication",
        "  No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib",
        "  No ongoing or active infection",
        "  No symptomatic congestive heart failure",
        "  No unstable angina pectoris",
        "  No cardiac arrhythmia",
        "  No psychiatric illness or social situation that would preclude study compliance",
        "  No other uncontrolled illness",
        "  No gastrointestinal (GI) tract disease that would preclude ability to take oral medication",
        "  No malabsorption syndrome",
        "  No requirement for IV alimentation",
        "  No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)",
        "  PRIOR CONCURRENT THERAPY:",
        "  No prior chemotherapy, immunotherapy, radiotherapy, or hormonal therapy for breast cancer",
        "  No prior treatment with epidermal growth factor receptor targeting therapies",
        "  No prior surgical procedures affecting absorption",
        "  No prior surgery for breast cancer",
        "  At least 14 days since prior and no concurrent CYP3A4 inducers, including any of the following:",
        "  Dexamethasone or dexamethasone equivalent dose  1.5 mg/day, including any of the following:",
        "  Cortisone ( 50 mg/day)",
        "  Hydrocortisone ( 40 mg/day)",
        "  Prednisone ( 10 mg/day)",
        "  Methylprednisolone ( 8 mg/day)",
        "  Phenytoin",
        "  Carbamazepine",
        "  Phenobarbital",
        "  Efavirenz",
        "  Nevirapine",
        "  Rifampin",
        "  Rifabutin",
        "  Rifapentine",
        "  Hypericum perforatum (St. John's wort)",
        "  Modafinil",
        "  At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:",
        "  Clarithromycin",
        "  Erythromycin",
        "  Troleandomycin",
        "  Delavirdine",
        "  Ritonavir",
        "  Indinavir",
        "  Saquinavir",
        "  Nelfinavir",
        "  Amprenavir",
        "  Lopinavir",
        "  Itraconazole",
        "  Ketoconazole",
        "  Voriconazole",
        "  Fluconazole (doses up to 150 mg/day are permitted)",
        "  Nefazodone",
        "  Fluvoxamine",
        "  Verapamil",
        "  Diltiazem",
        "  Cimetidine",
        "  Aprepitant",
        "  Grapefruit or its juice",
        "  At least 6 months since prior and no concurrent amiodarone",
        "  At least 2 days since prior and no concurrent gastric pH modifiers*, including any of the following:",
        "  Cimetidine",
        "  Ranitidine",
        "  Nizatidine",
        "  Famotidine",
        "  Omeprazole",
        "  Esomeprazole",
        "  Rabeprazole",
        "  Pantoprazole",
        "  Lansoprazole",
        "  NOTE: *Antacids are allowed within 1 hour before and after administration of study drug",
        "  No other concurrent investigational agents",
        "  No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or antitumor hormonal therapy",
        "  No concurrent herbal (alternative) medicines",
        "  No concurrent combination antiretroviral therapy for HIV-positive patients",
        "  Concurrent bisphosphonates allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Clinical Response Rate (cRR)",
        "  cRR measured by RECIST for target lesions assessed by clinical exam+ mammogram+ ultrasound (US). cRR is defined as number of patients who's best response in any of the assessments (clinical exam/mammogram/US) is CR+PR. Response will be defined as one of the following in either clinical exam, mammogram or US: Complete Response (CR)-Disappearance of all target lesions. Partial Response (PR)>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum.",
        "  Stable Disease-neither sufficient shrinkage to qualify for Partial disease nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD while on study.",
        "  Progressive Disease <=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.",
        "  Time frame: At Baseline, then before each treatment cycle begins and after 4 cycles of study treatment (1 cycle = 21 days)",
        "Results 1: ",
        "  Arm/Group Title: Treatment With Lapatinib and Abraxane",
        "  Arm/Group Description: 30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.",
        "  lapatinib ditosylate: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.",
        "  paclitaxel albumin-stabilized nanoparticle formulation: 30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 29",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 6",
        "  Partial Response: 18",
        "  Stable Disease: 5",
        "  Progressive Disease: 0",
        "  Clinical Response Rate: 24"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/30 (6.67%)",
        "  Dry Eyes  [1]1/30 (3.33%)",
        "  Diarrhea  [2]1/30 (3.33%)"
    ]
}